title: Effects of glucose-free dialysis solutions on human peritoneal mesothelial cells.
abstract: BACKGROUND
  Glucose-free dialysis solutions may be more biocompatible owing to the physiological pH and the lack of glucose degradation products, and the effects can be reflected by the changes in some markers of peritoneal mesothelial cells (PMC).
  
  
  METHODS
  Peritoneal effluents were collected in 17 CAPD patients after one daily exchange of glucose-containing dialysate to Nutrineal (1.1% amino acid-based PDF), and human PMC were cultured from peritoneal effluent and treated with various peritoneal dialysis (PD) solutions.
  
  
  RESULTS
  The level of cancer antigen 125 (CA125) in peritoneal effluent increased significantly after using Nutrineal for 3 months (p = 0.045), whereas that of procollagen I peptide (PICP) remained unaltered. Production of CA125 by human PMC showed a time-responsive increase after stimulation with Nutrineal and Extraneal (icodextran-based PDF). An increased expression of CA125 was observed in cultured human PMC treated with various PD solutions, and the increase induced by Nutrineal was lower than that induced by 4.25% Dianeal and Extraneal. A lower increase was also observed for lactate dehydrogenase (LDH). The levels of heat shock protein 70 (HSP70), however, were not altered.
  
  
  CONCLUSIONS
  Nutrineal is more biocompatible to the peritoneal membrane than the conventional PD solutions tested herein, reflected by both the in vivo and in vitro response of CA125.
authors: Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC.
authors: Jer-Ming
authors: JM
authors: Chang
authors: Shih-Pi
authors: SP
authors: Lin
authors: Yung-Hsiung
authors: YH
authors: Lai
authors: Hung-Chun
authors: HC
authors: Chen
mesh_terms: D002478:Cells, Cultured; D015314:Dialysis Solutions / Q000494:pharmacology*; D004847:Epithelial Cells / Q000187:drug effects; D004848:Epithelium / Q000187:drug effects*; D005260:Female; D005947:Glucose / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000379:methods*; D010537:Peritoneum / Q000187:drug effects; D014511:Uremia / Q000628:therapy
chemical_list: D015314:Dialysis Solutions; D005947:Glucose